Leerink Partners analyst David Risinger warned his clients on Sunday that the tariff risks to the industry are ‘underappreciated.’
Related Posts
Pharma is hopeful about Trump’s second term — here’s what to expect for drugmakers
Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation and patient access to treatments.
Russia and U.S. begin talks on ending the war in Ukraine, but Europe can’t agree a peacekeeping plan
The meeting between U.S. Secretary of State Marco Rubio and Russian Foreign Minister Lavrov marks the first formal sit-down meeting between top U.S. and Russian […]
Alibaba-affiliate Ant combines Chinese and U.S. chips to slash AI development costs
Alibaba-affiliate Ant Group is using both Chinese and U.S.-made semiconductors to make its AI more efficient, according to a source familiar with the matter.